PFIZER2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member PFIZER2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2021-04-01 2022-03-31 2021-07-16 INR Crores First quarter Single segment Pharmaceuticals 2021-04-01 2021-06-30 Unaudited Standalone 7491700000.00 122400000.00 7614100000.00 945000000.00 1622900000.00 177300000.00 943600000.00 22500000.00 270000000.00 945500000.00 4926800000.00 2687300000.00 0.00 2687300000.00 707900000.00 -19700000.00 688200000.00 0.00 1999100000.00 0.00 0.00 0.00 0.00 1999100000.00 1500000.00 2000600000.00 0.00 0.00 457500000.00 10 43.69 43.69 0.00 0.00 43.69 43.69 1.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on July 28, 2021 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated July 5, 2016. 3. The financial results for the quarter ended June 30, 2021 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerindia.com 4. Figures for the quarter ended March 31, 2021 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2020 which were subject to a limited review by the statutory auditors. 5. The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. 6. The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of June 30, 2021. Other Expenses 945500000.00